Thyrocare - Results for March 2024

1) Consolidated revenue: Rs 187.2 crore compared to Rs 154.2 crore during Q4FY24, change 21% YoY with Pathology and Radiology segments growing by 23% YoY and 7% YoY respectively. 2) PAT: Rs 21.3 crore compared to Rs 17.2 crore during Q4FY24, change 24%. 3) Reported EBITDA: Rs 57.4 crore compared to Rs 33.8 crore during Q4FY24, change 70%. 4) Total volume in FY25 grew to 167.9 million, largest by far on volume. 5) Revenue from franchise surged by 22% YoY, and partnership revenue saw 24% YoY growth. 6) Consolidated gross margin stood at 74%, and normalized EBITDA margin was 35%. 7) Standalone normalized EBITDA grew by 72% YoY, while PAT* increased by 72% YoY. 8) Consolidated normalized EBITDA grew by 78% YoY, while PAT* increased by 88% YoY. 9) This is all for information. This is not a buy/sell call. Thank you, Technofunda24